Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment

被引:8
|
作者
Chen, Jialiang [1 ]
Xue, Dongying [3 ]
Gao, Fangyuan [1 ]
Tao, Le [3 ]
Li, Yuxin [1 ]
Zhang, Qun [2 ]
Wang, Rui [1 ]
Sun, Le [2 ]
Yang, Xue [1 ]
Liu, Yao [1 ]
Zhu, Bingbing [2 ]
Niu, Shuaishuai [1 ]
Wang, Xianbo [1 ]
机构
[1] Capital Med Univ, Beijing Ditan Hosp, Ctr Integrat Med, Beijing 100015, Peoples R China
[2] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Gastroenterol, Beijing, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Infect Dis, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
biochemical response; factors; primary biliary cholangitis; score model; ursodeoxycholic acid; LONG-TERM PROGNOSIS; OBETICHOLIC ACID; HEPATOCELLULAR-CARCINOMA; CIRRHOSIS; BILIRUBIN; AMINOTRANSFERASE; AUTOANTIBODIES; MANAGEMENT; DIAGNOSIS; FIBROSIS;
D O I
10.1097/MEG.0000000000001186
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response. Patients and methods A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria. We determined independent factors of the biochemical response by univariate and multivariate analyses. Then, we established a predictive score model on the basis of regression coefficients after adjusted multivariate analyses. Results The median follow-up duration in the derivation and the verification group was 12.9 and 12.2 months, respectively. Multivariate logistic regression analysis after adjusting for sex and age indicated that First-UDCA treatment [odds ratio (OR)=2.543, 95% confidence interval (CI): 1.234-5.240, P=0.011], baseline alanine aminotransferase level (OR=1.265, 95% CI: 1.089-1.471, P=0.002), and baseline total bilirubin level (OR=0.571, 95% CI: 0.420-0.776, P<0.001) were independent factors that influenced the biochemical response in PBC patients after 1 year of UDCA treatment. Therefore, the resulting biochemical response prediction score model represented the sum of the points corresponding to these three variables. The area under the receiver operating characteristic curve of the score model in the derivation group and the verification group was 0.763 (95% CI: 0.701-0.817, P<0.001) and 0.798 (95% CI: 0.681-0.887, P<0.001), respectively. Conclusion We developed and verified an easy-to-use scoring model for the first time, which showed excellent predictive value for the biochemical response in PBC patients.
引用
收藏
页码:1352 / 1360
页数:9
相关论文
共 50 条
  • [1] Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis
    Brunet, Eduard
    Hernandez, Leticia
    Miquel, Mireia
    Sanchez-Delgado, Jordi
    Dalmau, Blai
    Valero, Oliver
    Vergara, Mercedes
    Casas, Meritxell
    MEDICINA CLINICA, 2019, 152 (10): : 377 - 383
  • [2] Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
    Shu, Yanyun
    Song, Yuhu
    Bai, Tao
    Pan, Xiaoli
    Shang, Haitao
    Yang, Ling
    Ye, Jin
    Du, Fan
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (02) : 187 - 193
  • [3] Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features
    Wen, Maoyao
    Men, Ruoting
    Fan, Xiaoli
    Shen, Yi
    Ni, Ping
    Hu, Zhichao
    Yang, Li
    DIGESTIVE DISEASES, 2021, 39 (04) : 366 - 374
  • [4] Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
    van Hooff, M. C.
    Werner, E.
    van der Meer, A. J.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 14 - 21
  • [5] The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis
    Namisaki, Tadashi
    Fujinaga, Yukihisa
    Moriya, Kei
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2021, 51 (01) : 31 - 38
  • [6] Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis
    Tang, Libo
    Zhong, Ruihua
    He, Xuanqiu
    Wang, Weibin
    Liu, Jinhong
    Zhu, Youfu
    Li, Yongyin
    Hou, Jinlin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (03) : 659 - 666
  • [7] A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
    Li, Chunlei
    Zheng, Kunyu
    Chen, Yiran
    He, Chengmei
    Liu, Suying
    Yang, Yunjiao
    Li, Mengtao
    Zeng, Xiaofeng
    Wang, Li
    Zhang, Fengchun
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [8] Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era Role of Scoring Systems
    Goel, Aparna
    Kim, Woong Ray
    CLINICS IN LIVER DISEASE, 2018, 22 (03) : 563 - +
  • [9] Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
    Chang, Jong-In
    Kim, Jung Hee
    Sinn, Dong Hyun
    Cho, Ju-Yeon
    Kim, Kwang Min
    Oh, Joo Hyun
    Park, Yewan
    Sohn, Won
    Goh, Myung Ji
    Kang, Wonseok
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung-Woon
    GUT AND LIVER, 2023, 17 (04) : 620 - 628
  • [10] Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis
    Gazda, Jakub
    Drazilova, Sylvia
    Gazda, Matej
    Janicko, Martin
    Koky, Tomas
    Macej, Marian
    Carbone, Marco
    Jarcuska, Peter
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (10) : 1318 - 1327